-

ArteraAI and GenesisCare Partner to Launch the First Australian-Based Clinical Trial

SAN FRANCISCO & SYDNEY--(BUSINESS WIRE)--ArteraAI, the developer of multimodal artificial intelligence (MMAI) based predictive and prognostic cancer tools, today announced a strategic collaborative agreement with GenesisCare, an integrated cancer care provider.

The agreement allows for ArteraAI and GenesisCare to collaborate in Australia to generate real-world data on AI tools guiding treatment decisions as part of a new clinical trial.

“We are honored to be able to partner with GenesisCare to provide the clinical community in Australia a way to personalize care for their patients,” said Andre Esteva, co-founder and CEO of ArteraAI.

ArteraAI and GenesisCare share a commitment to clinical innovation and advancing precision medicine, with the aim of improving the lives of patients with localized prostate cancer.

“Our research partnership with ArteraAI aligns with our aim to offer personalized and patient-centric care in communities across Australia,” said Professor Jarad Martin, GenesisCare Radiation Oncologist.

About ArteraAI

ArteraAI is a leading precision medicine company developing AI tools to personalize cancer therapy.

ArteraAI’s multimodal artificial intelligence (MMAI) biomarker tool leverages a unique algorithm that assesses digital images from a patient’s biopsy and learns from a patient's clinical data. The AI combines this information to predict whether a patient will benefit from a particular therapy and determine their prognosis.

About GenesisCare Australia

GenesisCare is an integrated cancer care provider that aims to change the face of cancer care with modern treatments and techniques designed to achieve the best possible life outcomes for patients. In Australia, GenesisCare provides care to approximately 30,000 patients a year across 48 locations in metro and regional Victoria, New South Wales, Queensland, South Australia, and Western Australia. GenesisCare’s vision is to offer patients personalized, high-quality care throughout their cancer journey. For more information, visit www.genesiscare.com.

Contacts

Media:
Lesley Swiger
Antenna
artera@antennagroup.com
(202) 869-1612

Industry:

ArteraAI

Release Versions
English

Contacts

Media:
Lesley Swiger
Antenna
artera@antennagroup.com
(202) 869-1612

More News From ArteraAI

Artera Unveils Data Demonstrating Prognostic and Predictive Utility in Breast Cancer at SABCS 2025

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, today announced that three abstracts will be presented at the San Antonio Breast Cancer Symposium (SABCS), held December 9-12. The studies collectively highlight the prognostic and predictive power of Artera’s MMAI model to help personalize treatment decisions, particularly in evaluating chemotherapy benefit in post-menopausal women. Leveraging data fr...

Artera Unveils Four Presentations at ASTRO 2025 Illustrating its Multimodal Artificial Intelligence (MMAI) Platform’s Scalability, Speed, and Potential to Personalize Treatment Decisions for Multiple Cancers

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, will present four abstracts at the 2025 American Society for Radiation Oncology Annual Meeting (ASTRO). The presentations collectively showcase Artera’s vision to advance the frontier of personalized cancer care, including the first validation of the ArteraAI Prostate Test in an Asian patient cohort; the rapid development and validation of its MMAI bio...

Artera Receives U.S. FDA De Novo Marketing Authorization for AI-Digital Pathology Software Revolutionizing Prostate Cancer Care

SAN FRANCISCO--(BUSINESS WIRE)--Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, announced today that the U.S. Food and Drug Administration (FDA) has granted De Novo authorization for ArteraAI Prostate, establishing it as the first and only AI-powered software authorized to prognosticate long-term outcomes for patients with non-metastatic prostate cancer. ArteraAI Prostate is now recognized as an FDA-regulated Software as a Medical...
Back to Newsroom